不同时期慢性HBV感染者血清IFN-λs水平的变化  

Serum interferon-lambda of different stages in patients with chronic HBV infection

作　　者：杜以真[1] 王晓花[1] 张孝国[1] 张纵[1] 阚晓[1] 徐皖苏[1] 

机构地区：[1]山东大学附属济南市传染病医院,济南250021

出　　处：《新医学》2014年第2期119-122,共4页Journal of New Medicine

摘　　要：目的了解不同时期慢性HBV感染者血清IFN-λs水平,探讨其变化与慢性HBV感染进程的关系。方法选择120例慢性HBV感染者,其中HBV携带者、慢性乙型病毒性肝炎(慢乙肝)患者、乙肝肝硬化患者、HBV相关肝癌患者各30例,以20名健康人为对照。采用双抗体夹心ELISA法,检测各组研究对象血清IFN-λs(IL-29、IL-28A和IL-28B)水平。结果慢乙肝、乙肝肝硬化、HBV相关肝癌患者的血清IFN-λ1(IL-29)水平均明显低于健康对照组(P均<0.01),慢乙肝、乙肝肝硬化、HBV相关肝癌患者血清IFN-λ1(IL-29)水平明显低于HBV携带者(P均<0.01);HBV携带者血清IL-29水平与健康对照组相近(P>0.05)。各组慢性HBV感染患者的血清IFN-λ2(IL-28A)水平与健康对照组比较均无统计学意义(P>0.05)。HBV相关肝癌患者血清IFN-λ3(IL-28B)水平高于健康人、HBV携带者、慢乙肝患者、乙肝肝硬化患者(P均<0.01);HBV携带者、慢乙肝、乙肝肝硬化和健康对照组间血清IL-28B水平比较差异无统计学意义(P>0.05)。结论慢性HBV感染者血清IFN-λ1(IL-29)水平明显下降,而且HBV相关肝癌患者血清IFN-λ3(IL-28B)的水平明显升高,可能与肝癌的发生有关。Objective To study IFN-λs levels in patients with chronic hepatitis B virus （HBV）in-fections,and investigate the relationship between human type III interferons （IFN-λs）and chronic HBV infec-tion.Methods 1 20 chronic HBV infection patients were recruited,and divided into 4 groups：chronic HBV carriers,chronic hepatitis B patients,HBV related cirrhosis and HBV related hepatocellular carcinoma pa-tients.20 healthy people were as negative controls.IFN-λs levels were detected by Enzyme-linked immunosor-bent assay （ELISA）.Results Levels of IFN-λ1 （IL-29）in chronic hepatitis B,cirrhosis,hepatocellular carcinoma patients were lower than that in the controls （P〈0.01 ）and chronic HBV carriers,（P〈0.01 ）. There was no significant difference between chronic HBV carriers and negative controls （P〉0.05）.No signifi-cant difference were found in IFN-λ2 （IL-28A）of all five groups （P＆gt;0.05）.The level of IFN-λ3 in hepato-cellular carcinoma patients was the highest among all groups.Conclusion IFN-λ1 level is decreased in chron-ic HBV infection patients when compared with healthy people.In addition,high level of serum IFN-λ3 may be related to the occurrence of hepatocellular carcinoma.

关 键 词：血清Ⅲ型干扰素 慢性HBV感染 白细胞介素 

分 类 号：R512.62[医药卫生—内科学]